People with systemic sclerosis (SSc) show a wide range of eye complications, with dry eye disease, eyelid…
Articles by Marta Figueiredo, PhD
Patients with scleroderma may need longer-term treatment with Adempas (riociguat) to heal their digital ulcers, results of…
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to Ofev (nintedanib) as a potential therapy for progressive fibrosing interstitial…
The U.S. Food and Drug Administration (FDA) has approved Ofev (nintedanib) as the first therapy to slow lung function decline in…
Patient-reported symptoms — specifically those related to blood vessel, skin, and lung function — may be used to indicate changes…
Specific features of lesions associated with active disease in juvenile localized scleroderma — such as redness but not skin thickness —…
The presence of B-cells — a type of white blood cell — in the skin of scleroderma patients may predict…
The presence of a specific scleroderma subtype and autoantibodies may be reliable factors to identify a distinct cancer risk in…
Almost a quarter of systemic sclerosis (SSc) patients with reduced gas exchange develop pulmonary hypertension (PH) within three years,…
Researchers have discovered that plasmacytoid dendritic cells (pDCs) contribute to the skin scarring in scleroderma, making them a possible target…